Phaseline

Targets › IDH1

IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic): drug programs, companies and trials

15 programs from 14 companies in 66 trials: 27 Phase 2, 24 Phase 1, 14 Phase 3, 1 Phase 4; Oncology, Hematology, Other; next expected readout Nov 2026.

Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase. Can also use 2-oxoglutarate as substrate and catalyze the reduction of 2-oxoglutarate to R-2-hydroxyglutarate. (UniProt, O75874)

Open in Phaseline: the race on IDH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rigel PharmaceuticalsOlutasidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 4AML (Acute Myeloid Leukemia); High Grade Glioma; Targeted Therapy; Myelodysplastic Syndromes …Apr 2027
HutchmedHMPL-306
IDH1/IDH2 inhibitor
IDH1, IDH2Phase 3Acute Myeloid Leukemia; Gliomas Harboring IDH1 and/or IDH2 MutationsDec 2026
Chia Tai Tianqing Pharmaceutical GroupTQB3454 tablets
Selective IDH1 mutant enzyme inhibitor
IDH1Phase 3Biliary CarcinomaDec 2026
Servier Affaires MédicalesIvosidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 3Acute Myeloid Leukemia (AML); Cholangiocarcinoma; Newly Diagnosed Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia …Oct 2027
Servier Bio-InnovationIvosidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 3Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen; IDH1-Mutated MalignanciesFeb 2028
Nuvation BioSafusidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 3Glioma; Grade 2 IDH1-mutant GliomaDec 2028
ServierVorasidenib (S095032)
IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1, IDH2Phase 3Residual or Recurrent Grade 2 IDH Mutant GliomaOct 2030
Institut de Recherches Internationales Servier (I.R.I.S.)Vorasidenib
IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1, IDH2Phase 2Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation; Severe Hepatic Impairment; Grade 2 Glioma; Astrocytoma, IDH-Mutant, Grade 3 …Nov 2026
Daiichi SankyoDS-1001b
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 2WHO Grade II GliomaFeb 2027
ServierIvosidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 2Cholangiocarcinoma Non-resectableMay 2027
Kissei PharmaceuticalOlutasidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 2Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid LeukemiaSep 2030
Eli LillyLY3410738
Covalent isocitrate dehydrogenase (IDH) inhibitor
IDH1, IDH2Phase 1Acute Myeloid Leukemia (AML); CholangiocarcinomaMay 2027
Katy Peters, MD, PhDPEPIDH1M vaccine
Tumor-specific peptide vaccine targeting IDH1 mutations
IDH1Phase 1Low Grade Glioma of BrainAug 2027
NovartisIDH305
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 1Advanced Malignancies That Harbor IDHR132 MutationsOct 2030
Bristol-Myers SquibbIvosidenib (AG-120)
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 1Leukemia, Myeloid, Acute–

Conditions

Acute Myeloid Leukemia (12) Acute Myeloid Leukemia (AML) (3) Cholangiocarcinoma (3) Newly Diagnosed Acute Myeloid Leukemia (AML) (2) Myelodysplastic Syndromes (2) AML (Acute Myeloid Leukemia) (2) IDH1 Mutation (2) Acute Myeloid Leukemia With Gene Mutations (2) AML (2) Low Grade Glioma of Brain (2) Glioma (1) Grade 2 IDH1-mutant Glioma (1)

Modalities

small molecule (14), other (1)

Companies

Servier (2) Eli Lilly (1) Nuvation Bio (1) Bristol-Myers Squibb (1) Kissei Pharmaceutical (1) Servier Affaires Médicales (1) Katy Peters, MD, PhD (1) Hutchmed (1) Rigel Pharmaceuticals (1) Servier Bio-Innovation (1) Novartis (1) Daiichi Sankyo (1) Institut de Recherches Internationales Servier (I.R.I.S.) (1) Chia Tai Tianqing Pharmaceutical Group (1)

Related targets

IDH2 (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.